ImmuPharma’s CEO Tim McCarthy and CSO Dr Sébastien Goudreau talk with Proactive Investor about the Company’s latest milestone — the filing of a new patent application for its lead autoimmune drug therapy, P140, described as the world’s first “immunormaliser’ – September 2025